Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
Basel, May 30, 2017 – Novartis announced findings from a pilot examine (NCT02640209) of CTL119 in combination with ibrutinib* in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who had been taking ibrutinib for at least six months and who were not in accomplish remission. Continue reading Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients Swiss Stock Exchange: NOVN